SCHEDULE 13G/A: Gilead Sciences Discloses 3.6% Stake in Ikena Oncology
Beneficial Ownership Report (Schedule 13G)
Gilead Sciences, Inc. has filed an amended Schedule 13G, revealing a beneficial ownership of 3.6% of Ikena Oncology, Inc.'s common stock as of December 31, 2024.
Summary
- Gilead Sciences, Inc. reported beneficial ownership of 1,521,312 shares of Ikena Oncology, Inc.'s common stock.
- This ownership represents 3.6% of Ikena Oncology's common stock.
- The percentage is calculated based on 42,042,645 shares of common stock outstanding as of November 1, 2024, as disclosed in Ikena Oncology's Quarterly Report on Form 10-Q filed on November 7, 2024.
- The calculation excludes 6,215,466 shares of non-voting common stock.
- Gilead Sciences holds sole voting power and sole dispositive power over all 1,521,312 shares.
- The filing certifies that the securities were not acquired or held for the purpose of changing or influencing the control of Ikena Oncology.
Sentiment
Score: 6
Explanation: The document is a factual disclosure of beneficial ownership. While it doesn't contain explicit sentiment, a significant stake by a major industry player like Gilead Sciences in a smaller biotech company like Ikena Oncology could be perceived as a moderately positive signal by the market, suggesting potential strategic alignment or confidence, hence a slightly positive score.
Future Outlook
NA
Industry Context
This filing indicates a significant investment by Gilead Sciences, a major biopharmaceutical company, into Ikena Oncology, a biotechnology firm. Such investments can signal strategic interest or confidence from larger industry players in the smaller company's pipeline or technology, common in the highly collaborative and acquisition-prone pharmaceutical and biotech sectors.
Stakeholder Impact
- Shareholders of Ikena Oncology, Inc. are impacted by the disclosure of a significant institutional holder, Gilead Sciences, which could influence market perception and trading activity.
- The presence of a major pharmaceutical company as a significant shareholder might be viewed positively by investors, potentially signaling future collaborations or strategic interest.
Key Dates
| Date | Description |
|---|---|
| 2024-11-01 | Date as of which 42,042,645 shares of Ikena Oncology's common stock were outstanding, used for percentage calculation. |
| 2024-11-07 | Date Ikena Oncology's Quarterly Report on Form 10-Q was filed, disclosing outstanding shares. |
| 2024-12-31 | Date of event which requires the filing of this Schedule 13G statement. |
| 2025-02-11 | Date as of which the reported beneficial ownership numbers (rows 5, 7, and 9) reflect Gilead Sciences' holdings. |
| 2025-02-13 | Date the Schedule 13G statement was signed and filed by Gilead Sciences. |
Keywords
Gilead Sciences, Ikena Oncology, Beneficial Ownership, Schedule 13G, SEC Filing, Common Stock, Biotechnology, Pharmaceuticals, Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.